Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes

Fig. 3

PCSK9-regulated migratory capacity of monocytes. PCSK9 decreases the LDLR on the cell surface of a monocyte. As a result, the accumulated circulating low-density lipoprotein-cholesterol (LDL-C) stimulates the expression of C–C chemokine receptor 2 (CCR2), which serves as the receptor of MCP-1. Thus, the monocyte can migrate towards MCP-1 and accumulate in the arterial wall

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840